Biogen Management

Management criteria checks 4/4

Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 1.75 years. total yearly compensation is $4.07M, comprised of 39.3% salary and 60.7% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth CHF1.23M. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.

Key information

Chris Viehbacher

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage	39.3%
CEO tenure	1.8yrs
CEO ownership	0.005%
Management average tenure	4.3yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Viehbacher's remuneration changed compared to Biogen's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

Compensation vs Market: Chris's total compensation ($USD4.07M) is about average for companies of similar size in the Swiss market ($USD4.95M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Viehbacher (63 yo)

1.8yrs

Tenure

US$4,069,913

Compensation

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Viehbacher	President	1.8yrs	US$4.07m	0.0048% $ 1.2m
Michael McDonnell	Executive VP & CFO	4yrs	US$7.17m	0.013% $ 3.4m
Nicole Murphy	Head of Pharmaceutical Operations & Technology	2.6yrs	US$5.71m	0.0066% $ 1.7m
Susan Alexander	Executive VP & Chief Legal Officer	18.6yrs	US$6.70m	0.035% $ 9.1m
Rachid Izzar	Head of Global Product Strategy & Commercialization	3.6yrs	US$5.45m	0.0067% $ 1.7m
Robin Kramer	Senior VP & Chief Accounting Officer	5.8yrs	no data	0.0043% $ 1.1m
Charles Triano	Senior VP & Head of Investor Relations	1.4yrs	no data	no data
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	4.6yrs	no data	no data
Adam Keeney	Executive VP & Head of Corporate Development	1.3yrs	no data	0.00045% $ 115.1k
Ginger Gregory	Executive VP & Chief Human Resources Officer	7.1yrs	US$5.08m	0.0093% $ 2.4m
Alisha Alaimo	President & Head of North America	7.1yrs	no data	no data
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	7.1yrs	no data	no data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: BIIB's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Viehbacher	President	1.8yrs	US$4.07m	0.0048% $ 1.2m
Stephen Sherwin	Independent Director	14.4yrs	US$435.32k	0.013% $ 3.3m
William Hawkins	Independent Director	5.2yrs	US$425.73k	0.0045% $ 1.1m
Caroline Dorsa	Independent Chair of the Board	14.6yrs	US$646.13k	0.017% $ 4.4m
Eric Rowinsky	Independent Director	14.4yrs	US$418.02k	0.014% $ 3.6m
Maria Freire	Independent Director	3.2yrs	US$412.90k	0.0031% $ 779.8k
Monish Patolawala	Independent Director	less than a year	no data	0.00092% $ 235.2k
Jesus Mantas	Independent Director	5.2yrs	US$433.23k	0.0051% $ 1.3m
Susan Langer	Independent Director	1.2yrs	US$334.53k	0.0019% $ 483.2k

5.2yrs

Average Tenure

65yo

Average Age

Experienced Board: BIIB's board of directors are considered experienced (5.2 years average tenure).

Biogen Management

Management criteria checks 4/4

Key information

Recent management updates

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Recent updates

Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023)

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$4.09 (vs US$7.25 in 2Q 2022)

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Insider recently sold CHF716k worth of stock

First quarter 2023 earnings released: EPS: US$2.69 (vs US$2.07 in 1Q 2022)

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$20.97 (vs US$10.44 in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Authorization Application for Lecanemab

Biogen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Biogen Names Priya Singhal as Executive Vice President, Head of Development

U.S. Food and Drug Administration Accepts Biogen Inc.'s Biologics License Application for BIIB800

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Biogen Inc. Announces European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of Als

Biogen Inc. Announces Executive Changes

Biogen Inc. Revises Revenue Guidance for the Full Year 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure